Shilpa Hattangadi, MD

Assistant Professor of Pediatrics (Hematology / Oncology) and of Pathology; Assistant Professor, Pathology

Research Interests

Disease Models, Animal; Erythropoiesis; Hematologic Diseases; Hematopoiesis; Heterochromatin; Histone Deacetylases; Histones; Microscopy, Confocal; Nucleocytoplasmic Transport Proteins; Chromatin Immunoprecipitation; Erythroid-Specific DNA-Binding Factors

Public Health Interests

Cancer; Cancer genetics; Child health; Chronic disease management; Data analysis; Genomics

Research Organizations

Pediatrics: Pediatric Hematology & Oncology


Stem Cell Center, Yale

Yale Cancer Center: Genomics, Genetics, and Epigenetics

Office of Cooperative Research

Research Summary

We are focused on understanding the terminal stages of normal red blood cell development, from terminally committed progenitors to circulating red blood cells (RBCs). This is important (1) to learn why certain RBC disorders develop in the first place, but also (2) to help overcome challenges in treatment of these disorders as well as develop new ones. Our most recent focus on red blood cell development has been on how enucleation is dependent on nuclear protein export, how the nucleus condenses, and how histones are replaced in the condensing red cell nucleus before it is extruded.

We are also interested in identifying new genetic causes and/or modifiers of bone marrow failure syndromes and are interested in creating new mouse models of cytopenias found in children using the humanized mouse system here at Yale. We are currently pursuing one such regulator which is a post-translational modifier of hematopoietic regulators and has been found to be mutated in MDS and AML.

Selected Publications

Full List of PubMed Publications

Edit this profile

Contact Info

Shilpa Hattangadi, MD
Patient Care Location
Pediatric Hematology & OncologySmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 7th floor

New Haven, CT 06511
View on map...
Mailing Address
Pediatric Hematology & OncologyPediatric Hematology-Oncology
333 Cedar Street

New Haven, CT 06520
Erythroid Terminal Differentiation

A set number of characteristic cell divisions (3 in mouse, 4 in humans) from the progenitor to the final erythroblast result in decreased cell size. A distinct expression program results in hemoglobin production, making the cytoplasm more eosinophilic. Nuclear condensation ensues and culminates in enucleation only in mammals. We study this last step of terminal erythropoiesis.